Bariatric Surgery Drops 20% as GLP-1 Drugs Reshape Obesity Treatment

The landscape of obesity treatment is shifting rapidly, and new data from multiple fronts reveal both the promise and the trade-offs of current approaches. For anyone focused on metabolic health, cardiovascular risk, and long-term wellbeing, these findings carry real practical weight.

The headline number: bariatric surgeries in the U.S. fell more than 20% in 2024, dropping below 200,000 for the first time since 2020. The likely driver is the explosive uptake of GLP-1 receptor agonists like semaglutide. However, a study in Annals of Surgery found that among adults with obesity, bariatric surgery was associated with greater lifetime reductions in atherosclerotic cardiovascular disease risk compared to GLP-1 drug use — a meaningful distinction for high-risk patients.

On the safety side, another study published in JAMA Network Open linked GLP-1 receptor agonist use to a modestly elevated risk of nonarteritic anterior ischemic optic neuropathy, a potentially vision-threatening condition. While the risk appears small, it adds to a growing list of considerations clinicians must weigh when prescribing these widely used drugs.

Beyond obesity drugs, researchers published machine-learning models in Nature Genetics and Nature Medicine that improve prediction of type 1 diabetes using genetic risk factors and stratify 10-year risk across 18 obesity-related complications. These tools could eventually help individuals and clinicians intervene earlier and more precisely.

Finally, a JAMA perspective highlighted that simply telling patients to exercise rarely works, and outlined structured best practices for prescribing exercise — particularly relevant as GLP-1 drugs can reduce muscle mass alongside fat. Preserving muscle through intentional exercise prescription is increasingly seen as essential to healthy, durable weight loss. Caveats apply: most findings here are observational or early-phase, and individual risk profiles vary considerably.